Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Top Stock Movers Now: Alphabet, Tesla, Carvana, Novo Nordisk, and More
Published: November 24, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes climbed Monday afternoon as tech stocks rallied, and as optimism about a rate cut by the Federal Reserve next month grew. The Dow rose 0.4% and the S&P 500 added 1.3%, while the tech-heavy Nasdaq surged over 2%.
Read More
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.
Published: November 24, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Read More
Novo Nordisk shares slide after semaglutide Alzheimer's trial misses primary goal
Published: November 24, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Novo Nordisk (NYSE:NVO) fell sharply on Monday after the Danish pharmaceutical giant said a late-stage trial testing its diabetes and weight-loss drug semaglutide in Alzheimer's disease did not meet its main objective. The Phase III Evoke and Evoke+ trials, which enrolled nearly 3,800 patients with early signs of cognitive decline, showed no meaningful impact on disease progression, Novo Nordisk said.
Read More
Failing Drug Stock Suffers Another Blow on Drug Trial Data
Published: November 24, 2025 by: Schaeffers Research
Sentiment: Negative
Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide.
Read More
Novo Nordisk stock slides as its Alzheimer's drug trials fail
Published: November 24, 2025 by: Fast Company
Sentiment: Negative
Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding.
Read More
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
Read More
3 Weight-Loss Drug Stocks To Consider For 2026
Published: November 21, 2025 by: Benzinga
Sentiment: Positive
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:
Published: November 21, 2025 by: WSJ
Sentiment: Positive
Plus, new hormone therapy guidelines, breast-cancer pills and obesity drug price cuts, in this edition of the WSJ Health newsletter.
Read More
Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
Published: November 21, 2025 by: Reuters
Sentiment: Positive
Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, bypassing traditional drug sales channels.
Read More
Novo Nordisk: Will Wegovy And Pipeline Spark Rally?
Published: November 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Thanks to Wegovy's approval as a treatment for NASH, its sales rose to DKK 20.35 billion in the 3rd quarter. Yes, Ozempic remains a "dark spot" in Novo Nordisk's GLP-1 franchise, but at the same time, its sales grew by 3.2% year on year.
Read More
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
Published: November 19, 2025 by: MarketBeat
Sentiment: Negative
For investors in Novo Nordisk NYSE: NVO, 2025 has been a challenging year. After reaching a 52-week high of over $112, the stock has declined by approximately 45%, reflecting mounting competitive pressures and concerns about slowing growth in its key GLP-1 franchise.
Read More
Novo Nordisk: A Rare Second Chance
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered guidance, and intensifying competition, but double-digit growth and strong pipeline remain intact. Valuation is compelling: Novo Nordisk trades near its lowest P/E in 20 years and offers a solid free cash flow yield, with intrinsic value estimates well above current price.
Read More
Novo Holdings to sell 7.8% stake in UK's Convatec, bookrunner says
Published: November 17, 2025 by: Reuters
Sentiment: Neutral
Novo Holdings, which controls obesity drugmaker Novo Nordisk , will sell 155 million shares, or about 7.8% of its stake, in British medical products maker Convatec Group , a bookrunner for the offering said on Monday.
Read More
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Read More
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It's a Worry for the Stocks.
Published: November 17, 2025 by: Barrons
Sentiment: Negative
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Read More
Novo Nordisk is now offering its anti-obesity drug for as low as $199 per month
Published: November 17, 2025 by: Invezz
Sentiment: Positive
Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patients will be able to access its anti-obesity treatments at that price for the first two months, the pharmaceutical behemoth confirmed in a press release today.
Read More
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration
Published: November 17, 2025 by: Investors Business Daily
Sentiment: Negative
Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Novo Nordisk: Long-Term Brand Dominance At A Bargain
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Positive
Dominant mega-caps with low debt deserve investors' attention. In times of prosperity, waste is common—and often sets the stage for strong cash generation when the cycle turns. Novo is enacted solid counter-measures: the CVS deal, the crackdown on compounders, and aggressive cost cutting.
Read More
Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
Published: November 13, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.
Read More
'Not been pretty': Novo Nordisk faces rare shareholder rebuke over board shake-up
Published: November 13, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote against a board shake-up forced through by its dominant shareholder, the Novo Nordisk Foundation.
Read More
Novo Nordisk CEO signals new appetite for risk in obesity deals
Published: November 12, 2025 by: Reuters
Sentiment: Positive
When Novo Nordisk CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer , he was not ready to give up just yet on the company and its portfolio of experimental obesity drugs.
Read More
WeightWatchers to sell Novo Nordisk's Wegovy pill after 2026 launch
Published: November 12, 2025 by: Reuters
Sentiment: Positive
WeightWatchers' CEO said on Wednesday it plans to sell Novo Nordisk's much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.
Read More
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
Published: November 12, 2025 by: CNBC
Sentiment: Positive
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
Read More
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
Read More
Virtus SGA International Growth Q3 2025 Portfolio Activity
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
At the beginning of the quarter, Virtus liquidated its position in Novo Nordisk (NVO) and used the proceeds to fund a new position in Japanese retail holding company, Fast Retailing (FRCOY). We also initiated a position in the Chinese technology company, Alibaba (BABA), by trimming a number of existing holdings. Additional shares were purchased in Adyen (ADYEY), Atlassian (TEAM), and SAP (SAP) on weakness, while positions in Arm Holdings (ARM) and L'Oreal (LRLCF) among others were trimmed on strength.
Read More
GLP-1 prices are dropping: Who exactly will benefit?
Published: November 11, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commercial plans. Half of Americans are covered by employer and private health plans, many of which don't cover GLP-1s for weight loss because of the cost.
Read More
3 Buy-And-Forget Dividend Stocks With Snowballing Payouts
Published: November 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
If the headline yield today is not something you're concerned with, and you pay more attention to how fast a yield can grow, then it's worth buying dividend stocks you can forget about for decades.
Read More
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Published: November 10, 2025 by: Proactive Investors
Sentiment: Positive
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406